NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): ETIOLOGY, CLINICAL FEATURES, DIAGNOSIS, TREATMENT AND PREVENTION

Palvanova Matlyuba ,Mamadaliev Mukhammad

Authors

Palvanova Matlyuba ,Mamadaliev Mukhammad Fergana medical institute of public health

Keywords:

NAFLD, non-alcoholic fatty liver disease, metabolic syndrome, obesity, diagnosis, treatment, liver fibrosis, inflammation.

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver disorders worldwide, strongly associated with metabolic syndrome and obesity. This review summarizes current understanding of NAFLD pathogenesis, diagnostic methods, and therapeutic options, highlighting recent advances and future perspectives in disease management.

References

Younossi ZM, et al. Global epidemiology of NAFLD—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.

Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.

Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84.

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836-1846.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922.

Sookoian S, Pirola CJ. Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Hepatology. 2017;65(1):147-159.

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.

Castera L. Non-invasive assessment of liver fibrosis in patients with NAFLD. Gastroenterology. 2019;156(5):1264-1281.

Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32(1):3-13.

Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.

Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.

Younossi ZM, et al. Obeticholic acid for non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-2196.

Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-S64.

Loomba R, et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging challenge. Hepatology. 2020;72(5):1823-1836.

Arab JP, et al. Gut-liver axis in NAFLD: mechanisms and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17(7):427-443.